UC

January 3, 2020January 3, 2020

Synedgen Given $259K Grant to Advance Work on Potential IBD Treatments

News

Synedgen will use a $259,000 Congressionally Directed Medical Research Programs (CDMRP) grant to advance work on potential treatments for inflammatory bowel disease (IBD). Specifically, the funds will enable completion of preclinical ... Read more

July 1, 2019July 1, 2019

Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces

News

IMU-838, Immunic Therapeutics‘ lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies ... Read more

January 15, 2018

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

News

The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug ... Read more